This research bridged the classic oncogene c-Myc and the new concept cuproptosis, proposed for the first time that cuproptosis may engaged in c-Myc-mediated breast cancer stemness, and identified a new cuproptosis-based scoring system that could be used for clinical applications. The gene discussed is MYC; the disease is breast carcinoma.